Treatment with the vaccine did not improve progression-free survival in patients with HPV16-positive cervical and anogenital tumors.

Certain members of MotivHealth's HSA-based insurance plans will have access to DecisionRx's medication therapy optimization program.

With A$45 million in funding, the group will focus on research developing safer therapies and clinical trial programs for pediatric cancer treatment.

Drugmakers and insurers are exploring different payment schemes for expensive, potentially curative treatments, particularly ones tied to patient response.

Seven of 67 patients who received the cerebral adrenoleukodystrophy gene therapy developed blood cancer, though most cases ...

The firm is gearing up for a registration-directed trial based on a positive Phase Ib readout and after discussions with US ...

The drugmaker wants to establish Enhertu in HER2-ultralow breast cancer and even HER2-negative tumors but remains committed to precision medicine strategies.

In a post hoc analysis within a prior Phase II study, the company found SP-624 improved symptoms in female patients with major depressive disorder.

In the INAVO120 trial, Itovebi added to Pfizer's Ibrance and fulvestrant doubled progression-free survival versus Ibrance and fulvestrant alone.

The firm plans to use the proceeds to advance its pipeline of T-cell receptor therapies and support their manufacturing, production, and commercialization.

The firm is evaluating leniolisib, which is already approved and sold under the brand name Joenja for APDS, in certain primary immunodeficiencies with immune dysregulation.

Researchers will develop therapies for urea cycle disorders and create a platform to rapidly develop treatments for other rare genetic disorders.